Focused on the cell therapy manufacturing bottleneck, Cellares turbocharges plans for 'shuttle' tech
When Cellares CEO and co-founder Fabian Gerlinghaus tore his ACL a few years ago, he was brought outside of a Bay Area hospital to the parking lot where he received an MRI inside a truck. He and his colleagues hope that the same can be done for cell therapy — one day — and they just received $82 million in funding to help do so.
Cellares on Wednesday bagged a Series B round, bringing its total funding to $100 million so far. Those funds will be used to develop the Cell Shuttle, a portable factory that Cellares hopes will disrupt the expensive and logistically complicated cell therapy manufacturing process.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.